Literature DB >> 1887164

Aspergillosis and lung defenses.

M R Elstad1.   

Abstract

Aspergillosis refers to any of the illnesses caused by fungi that are members of the genus Aspergillus. The diseases range from allergic responses that occur in the absence of fungal growth (asthma, hypersensitivity pneumonitis), to colonization with or without an allergic component (allergic bronchopulmonary aspergillosis, aspergilloma, saprophytic involvement of infarcted tissue), to invasion and destruction of lung parenchyma (invasive aspergillosis, chronic necrotizing pulmonary aspergillosis). The development of lung infection and/or disease depends on interaction among three factors: the characteristics of the fungus (virulence factors), the status of host defense mechanisms, and the type of exposure. The purpose of this article is to review these factors and their relationship to the clinical syndromes of aspergillosis.

Entities:  

Mesh:

Year:  1991        PMID: 1887164

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  7 in total

Review 1.  Infectious disease, the innate immune response, and fibrosis.

Authors:  Alessia Meneghin; Cory M Hogaboam
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

2.  Efficacy of TAK-457, a novel intravenous triazole, against invasive pulmonary Aspergillosis in neutropenic mice.

Authors:  Ryogo Hayashi; Naomi Kitamoto; Yuji Iizawa; Takashi Ichikawa; Katsumi Itoh; Tomoyuki Kitazaki; Kenji Okonogi
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Intranasal delivery of a truncated recombinant human SP-D is effective at down-regulating allergic hypersensitivity in mice sensitized to allergens of Aspergillus fumigatus.

Authors:  P Strong; K B M Reid; H Clark
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

4.  Chronic airway hyperreactivity, goblet cell hyperplasia, and peribronchial fibrosis during allergic airway disease induced by Aspergillus fumigatus.

Authors:  C M Hogaboam; K Blease; B Mehrad; M L Steinhauser; T J Standiford; S L Kunkel; N W Lukacs
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

5.  Immunosuppressive effects of CCL17 on pulmonary antifungal responses during pulmonary invasive aspergillosis.

Authors:  Kristin J Carpenter; Cory M Hogaboam
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

6.  Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils.

Authors:  T Madan; U Kishore; A Shah; P Eggleton; P Strong; J Y Wang; S S Aggrawal; P U Sarma; K B Reid
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

7.  Differential cell count and lymphocyte subsets in bronchoalveolar lavage during pneumonia with and without peripheral neutropenia.

Authors:  M von Eiff; O Schlingheider; F Schulze; M Zühlsdorf; J van de Loo
Journal:  Lung       Date:  1995       Impact factor: 2.584

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.